Capmatinib - Novartis Oncology
Alternative Names: INC-280; INCB-028060; INCB-28060; TABRECTA; TabrectaLatest Information Update: 14 Dec 2023
At a glance
- Originator Incyte Corporation
- Developer Array BioPharma; Novartis Oncology
- Class Antineoplastics; Benzamides; Fluorobenzenes; Heterocyclic bicyclo compounds; Imidazoles; Quinolines; Small molecules; Triazines
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase II Glioblastoma; Liver cancer; Malignant melanoma; Renal cell carcinoma; Solid tumours
- Phase I/II Breast cancer; Colorectal cancer; Head and neck cancer
- No development reported Triple negative breast cancer
Most Recent Events
- 31 Oct 2023 Novartis completes the phase-III GeoMETry-III trial in Non-small cell lung cancer in Belgium, Germany, Brazil, Bulgaria, France, India, Italy, South Korea, Netherlands, Hungary, Lithuania, Portugal and Spain (PO) (NCT04427072) (EudraCT2020-001578-31)
- 20 Oct 2023 Efficacy and adverse event data from a phase III GeoMETry-III trial in Non-small cell lung cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 03 Oct 2023 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT05567055)